Home/Vitara Biomedical/Janene Fuerch

JF

Janene Fuerch

Neonatology Advisor

Vitara Biomedical

Therapeutic Areas

Neonatology Premature Birth

Vitara Biomedical Pipeline

Drug	Indication	Phase
EXTEND	Support for extremely premature newborns (e.g., 22-28 weeks gestation) to improve survival and reduce severe morbidity	Pre-clinical / Early Feasibility

Leadership Team at Vitara Biomedical

Chief Executive Officer (CEO)

Co-Inventor, Medical Advisor

Co-Inventor, VP Preclinical Research

Chief Operations Officer

EVP Clinical, Regulatory and Quality

View full Vitara Biomedical profile